4D Molecular Therapeutics, Inc.
FDMT
$3.13
-$0.14-4.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.00K | 1.00K | 3.00K | 5.00K | 28.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.00K | 1.00K | 3.00K | 5.00K | 28.00K |
| Cost of Revenue | 40.70M | 43.09M | 38.48M | 31.86M | 27.87M |
| Gross Profit | -40.69M | -43.09M | -38.48M | -31.86M | -27.84M |
| SG&A Expenses | 12.94M | 13.03M | 12.65M | 10.60M | 10.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.64M | 56.12M | 51.14M | 42.46M | 38.16M |
| Operating Income | -53.62M | -56.12M | -51.13M | -42.46M | -38.14M |
| Income Before Tax | -47.97M | -49.67M | -43.84M | -34.95M | -32.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.97M | -49.67M | -43.84M | -34.95M | -32.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.97M | -49.67M | -43.84M | -34.95M | -32.40M |
| EBIT | -53.62M | -56.12M | -51.13M | -42.46M | -38.14M |
| EBITDA | -52.57M | -55.02M | -49.94M | -41.26M | -36.96M |
| EPS Basic | -0.86 | -0.89 | -0.79 | -0.63 | -0.66 |
| Normalized Basic EPS | -0.54 | -0.56 | -0.49 | -0.40 | -0.41 |
| EPS Diluted | -0.86 | -0.89 | -0.79 | -0.63 | -0.66 |
| Normalized Diluted EPS | -0.54 | -0.56 | -0.49 | -0.40 | -0.41 |
| Average Basic Shares Outstanding | 55.74M | 55.64M | 55.55M | 55.28M | 49.27M |
| Average Diluted Shares Outstanding | 55.74M | 55.64M | 55.55M | 55.28M | 49.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |